Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy.

Related Articles

Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy.

Oncoimmunology. 2017;6(2):e1265721

Authors: Lazear E, Ghasemi R, Hein SM, Westwick J, Watkins D, Fremont DH, Krupnick AS

Abstract
The use of high-dose interleukin-2 (IL-2) has fallen out of favor due to severe life-threatening side effects. We have recently described a unique way of directly targeting IL-2 to cytotoxic lymphocytes using a virally encoded immune evasion protein and an IL-2 mutant that avoids off-target side effects such as activation of regulatory T cells and vascular endothelium.

PMID: 28344875 [PubMed - in process]

http://ift.tt/2o5I63o